Form 4: Instil Bio Director George Matcham Granted 6,500 Stock Options

Instil Bio, Inc. Director George Matcham was granted 6,500 stock options with an exercise price of $26.75, vesting over 12 months or upon specific events.

Summary

• George Matcham, a Director of Instil Bio, Inc. (TIL), was granted 6,500 stock options.
• The transaction date for this grant was May 28, 2025.
• The exercise price for these stock options is $26.75 per share.
• The options will vest in 12 substantially equal monthly installments, commencing on June 28, 2025, contingent on Mr. Matcham's continuous service.
• Any unvested portion of the option will fully vest on the date of the next annual stockholder meeting, subject to continuous service.
• Full vesting will also occur upon Mr. Matcham's death, Disability, or a Change in Control, as defined in the company's 2021 Equity Incentive Plan.
• The expiration date for these stock options is May 27, 2035.
• Following this transaction, George Matcham beneficially owns 6,500 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal of continued commitment and alignment of interests between the director and shareholders. It is a standard compensation practice and does not indicate any negative operational or financial issues.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing long-term performance and value creation.
• This is a standard form of equity compensation, indicating continued commitment and engagement from the director.

Future Outlook

The vesting schedule of the stock options indicates a forward-looking incentive structure designed to retain the director and align their long-term interests with the company's performance and shareholder value.

Industry Context

The granting of stock options to directors is a common practice across various industries, particularly in biotechnology and growth-oriented companies, to attract and retain talent, and to align management and board interests with shareholder returns. This filing represents a routine insider transaction for compensation.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice in the biotechnology sector, comparable to compensation structures seen at companies like Moderna, BioNTech, or Gilead Sciences, which often use equity to incentivize long-term commitment and performance.
• The vesting schedule, including monthly installments and accelerated vesting upon specific events (death, disability, change in control), is typical for equity incentive plans in publicly traded companies, reflecting common corporate governance practices.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the options gain value only if the stock price increases above the exercise price.
• Employees: While this specific grant is to a director, it reflects the company's broader use of equity incentives, which can positively impact employee retention and motivation if similar plans are available to them.

Next Steps

• The stock options will begin vesting in monthly installments starting June 28, 2025.
• The options will continue to vest subject to the director's continuous service.

Key Dates

Keywords

Instil Bio, TIL, Stock Option, Director Compensation, Insider Transaction, Equity Grant, SEC Form 4, Executive Compensation, Vesting Schedule